Detection of Genetic Markers of Lung Cancer

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints revised (10)
    • Site contact updated
    v19
  2. Eligibility criteria expanded, about 13 words
    • Secondary endpoints revised (10)
    • Site contact updated
    • Study description expanded, about 1 word
    v18
  3. Secondary endpoints revised (10)
    • Site contact updated
    • Study description expanded, about 5 words
    v17
  4. Secondary endpoints revised (10)
    • Site contact updated
    • Study description expanded, about 3 words
    v16
  5. Eligibility criteria shortened, about 41 words
    • Secondary endpoints: 9 to 10
    • Study description expanded, about 24 words
    • Site contact updated
    v15
Show 13 earlier versionsHide 13 earlier versions
  1. Enrollment target: 4000 to 6000
    • Primary endpoint revised
    • Site contact updated
    • Eligibility criteria expanded, about 2 words
    v14
  2. Primary endpoints: 2 to 1
    • Secondary endpoints: 8 to 9
    • Study description expanded, about 39 words
    • Site contact updated
    v13
  3. Site contact updatedv12
  4. Site contact updatedv11
  5. Eligibility criteria shortened, about 16 words
    • Study description expanded, about 3 words
    v10
  6. Primary and study completion dates: Dec 2050
    • Site details revised
    • Study title expanded, about 4 words
    v9
  7. Site contact updatedv8
  8. 2 versions Re-verified since Oct 13, 2008, no change to tracked fieldsv6-v7
  9. Phase: Not applicable to Not specified
    • Enrollment target: 2000 to 4000
    • Secondary endpoints: details revised at 8 of 8 entries
    v5
  10. Re-verified, no change to tracked fieldsv4
  11. Site contact updatedv3
  12. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Trial Details
NCT Number NCT00280202
Lead Sponsor University of Pittsburgh
Collaborators: National Institutes of Health (NIH)
Conditions
(from sponsor)		 Lung Cancer
Related terms Carcinogenesis, Chromosome Aberrations, Lung Neoplasms
Enrollment 6,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov